Chronic PeriodontitisPhase 2NCT02767115
Grape Seeds Extract Gel as an Adjunct for the Treatment of Chronic Periodontitis
A Phase 2 study testing 2% GSE mucoadhesive gel and GSE free mucoadhesive gel in people with Chronic Periodontitis, run by Riyadh Colleges of Dentistry and Pharmacy at 1 site in Saudi Arabia.
Trial summary
The aim of this study was to formulate a mucoadhesive gel of grapes seed extract (GSE) followed by short-term clinical study for the effectiveness of this gel onto the pocket depth (PD), plaque index (PI), gingival index (GI), and bleeding on probing (BOP) when applied in periodontal pockets as an adjunct treatment… Read more about this study
- Who is it for?
- Ages 35 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Chronic Periodontitis
- What is being tested?
- 2% GSE mucoadhesive gel and GSE free mucoadhesive gel
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteSaudi Arabia
- Study dates
- Feb 2015to Sep 2015
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- being medically fit
- non-smokers
- has clinical diagnosis of chronic periodontitis with pockets depth of 5mm or greater along with evident radiographic bone Loss, and acceptance to provide an informed consent
Who cannot join
- pregnant patients
- breastfeeding mothers
- patients who are taking dietary supplements
- patients known to have grape's allergy
- patients with hypertension or bleeding disorders
- patients who have been under systemic or topical antibiotic treatments in the last 3 months
- smokers, and patients who are taking any medications that may interact with GSE
Trial locations and contacts
1 site in 1 country.
Saudi Arabia1 site
Riyadh colleges of dentistry and pharmacy
Riyadh, Riyadh Region, 11681
About this study
Official title: Grape Seeds Extract Gel as an Adjunct to Scaling and Root Planing for the Treatment of Chronic Periodontitis: A Pilot Clinical Study
The aim of this study was to formulate a mucoadhesive gel of grapes seed extract (GSE) followed by short-term clinical study for the effectiveness of this gel onto the pocket depth (PD), plaque index (PI), gingival index (GI), and bleeding on probing (BOP) when applied in periodontal pockets as an adjunct treatment for chronic periodontitis.
Read the detailed description
Before commencing with the study, the trial proposal was registered in the research center and ethical clearance was taken from the ethical committee (FUGRP/2014/182)
Materials used in the study::
- Pure Grape Seed Extract (GSE) supplied by pure bulk supplements (Bulksupplements, USA). It contains natural ingredient of more than 180 mg of proanthocyanidins for every 200 mg of serving size of the powder. GSE has been considered safe by the National Center for Complimentary and Integrative Health if used orally for up to 8 weeks of clinical trials
- Carbapol "CB 934" (Loba Chemie Pvt. Ltd., Mumbai)
- Sodium- carboxy methly cellulose "Na-CMC" supplied (Loba Chemie Pvt. Ltd., Mumbai)
- Sodium phosphate monobasic and sodium phosphate dibasic (Acros organic Ltd., Mumbai)
- Parabens (Loba Chemie Pvt. Ltd., Mumbai)
Method of preparation:
GSE mucoadhesive gel preparation:
- Formula 1: 2% GSE mucoadhesive gel based on minimum inhibitory concentration (MIC) and minimum toxic concentration (MTC) and depending on the concentration of adhesive polymers that were added to the formula.
Weighed CB 934 was dissolved in 50 ml of phosphate buffer of pH 6.6 with a vigorous mixing until it dissolved completely. Then, GSE and preservatives were dissolved in about 25 ml of phosphate buffer of pH 6.6. After that, the GSE solution was slowly added into the solution of CB 934 with a continuous stirring that was achieved by magnetic stirring at a speed of 100 rpm until a homogenous mixture was obtained. The gelling agent (Na-CMC) was added slowly under a continuous magnetic stirring. Then, the volume was increased up to 100 ml with the addition of phosphate buffer. Finally, the prepared gel was kept for 24 hours at room temperature (25°C) for a complete polymer dissolution.
- Formula 2: controlled gel without GSE. A controlled mucoadhesive gel was used in the clinical study to be compared with GSE gel. This control gel contained all above mentioned substances except for the GSE.
Microbial limit test:
One gram of the gel was suspended in 2.9 ml of phosphate buffer at pH 7.2. Different sterile media (Bismuth Sulfite Medium, Mannitol salt agar medium, Muller Hinton agar medium, cetrimide agar medium and sabaroud agar medium) were inoculated with the gel, then, incubated for 24 hours. After that, the media were examined to ensure no growth of bacterial genera.
Subjects:
A random sample of 24 patients were screened and examined. Five patients with mean age 43.5 ±7.9 years were found to comply with the study inclusion criteria
Baseline measurements and application of gels A total of 86 Sites of pocket depth (PD) of 5 mm and above were identified. Sites were divided randomly by split mouth technique into two groups: Test group (GSE group) who will receive GSE mucoadhesive gel (N=48) and Control group who will receive the control gel (N=38). The two prepared formulas were placed in identical containers providing that neither the patient, nor the clinician were aware of which was applied on which quadrant of the mouth "i.e. double blinded study".
In the first visit, an informed written consent was obtained from all patients. scaling and root planing (SRP) were performed by the same calibrated examiner using an ultrasonic scaler (miniPiezon, EMS, Switzerland) and Gracey curettes (Hu-Friedy Mfg, USA). Seven days after, the patients were recalled for clinical examination and baseline measurement (T0) were taken for Plaque index (PI), Gingival index (GI), Pocket depth (PD), and bleeding on probing (BOP) by a single calibrated examiner. PD was measured using a manual probe (UNC 15). PI and GI were assessed according to Silness and Loe (1964). BOP was assessed within 30 seconds after probing. In the same visit, the examiner applied the two prepared formulas into two opposite quadrants using a disposable syringe with a 23-gauge needle. Patients were given oral hygiene instructions and were instructed not to drink or eat for a minimum of 3 hours, not to brush the area for 24 hours and not to use mouth wash during the course of treatment.
The patients were recalled again after 3, 6, and 9 days to reapply the two formulas in the examined sites by the same examiner.
Revaluation The first re-evaluation visit (T1) was after 28 days from the baseline measurements (T0). During this visit, the calibrated clinician measured and recorded PI, GI, PD, BOP for all examined sites.
The second re-evaluation visit (T2) was after 6 months from the baseline measurements (T0) and the same measurements were retaken for all sites.
Statistical Package for the Social Sciences (SPSS) v20 package (IBM Corp) was used for statistical analysis. Significance of the change in PI, GI, and PD within each group were determined using paired t-test while the significance of difference in the change between the two groups was determined using the independent t-test. The difference was considered statistically significant at p < 0.05.
- Conditions
- Chronic Periodontitis
- Being tested
- 2% GSE mucoadhesive gel, GSE free mucoadhesive gel
- Medical subject headings
- Chronic Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2% GSE mucoadhesive gelDietary supplement
2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
GSE free mucoadhesive gelOther
GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
| Study group | Role | What they receive |
|---|---|---|
| GSE mucoadhesive gel | Experimental | 2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0 Receives: Dietary Supplement: 2% GSE mucoadhesive gel |
| Control mucoadhesive gel | Placebo comparator | GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0 Receives: Other: GSE free mucoadhesive gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline Pocket depth (PD) score
PD will be measured for all sites and compared with PD scores at T0
Measured: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Secondary outcomes (3)
Change from baseline Plaque index (PI)score
PI will be measured for all sites and compared with PI scores at T0
Measured: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Change from baseline Gingival index (GI)score
GI will be measured for all sites and compared with GI scores at T0
Measured: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Change from baseline Bleeding on probing (BOP)
BOP will be examined for all sites and number of sites with positive BOP will be compared with number of sites with positive BOP at T0
Measured: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2016 (estimated)
- Study startFeb 2015
- Primary completionSep 2015
- Study completionSep 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Riyadh Colleges of Dentistry and Pharmacy
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammad Ramadan Rayyan, Riyadh Colleges of Dentistry and Pharmacy
- Investigators
- Mohammad Rayyan, MDS, Principal investigator, Assistant professorTammam S Terkawi, MSc, Principal investigator, Lecturer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02767115
- Sponsor's protocol ID
- FUGRP/2014/182
- Status last verified
- May 2016
- First submitted
- 6 May 2016
- Last updated
- 10 May 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Grape Seeds Extract Gel as an Adjunct to Scaling and Root Planing for the Treatment of Chronic Periodontitis: A Pilot Clinical Study
- ClinicalTrials.gov ID
- NCT02767115
- Acronym / sponsor ID
- FUGRP/2014/182
- Conditions
- Chronic Periodontitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Riyadh Colleges of Dentistry and PharmacyUniversity, hospital or other
- Study start
- Feb 2015
- Primary completion
- Sep 2015 (actual)
- Study completion
- Sep 2015 (actual)
- First posted
- 10 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to formulate a mucoadhesive gel of grapes seed extract (GSE) followed by short-term clinical study for the effectiveness of this gel onto the pocket depth (PD), plaque index (PI), gingival index (GI), and bleeding on probing (BOP) when applied in periodontal pockets as an adjunct treatment for chronic periodontitis.
Detailed description
Before commencing with the study, the trial proposal was registered in the research center and ethical clearance was taken from the ethical committee (FUGRP/2014/182)
Materials used in the study::
- Pure Grape Seed Extract (GSE) supplied by pure bulk supplements (Bulksupplements, USA). It contains natural ingredient of more than 180 mg of proanthocyanidins for every 200 mg of serving size of the powder. GSE has been considered safe by the National Center for Complimentary and Integrative Health if used orally for up to 8 weeks of clinical trials
- Carbapol "CB 934" (Loba Chemie Pvt. Ltd., Mumbai)
- Sodium- carboxy methly cellulose "Na-CMC" supplied (Loba Chemie Pvt. Ltd., Mumbai)
- Sodium phosphate monobasic and sodium phosphate dibasic (Acros organic Ltd., Mumbai)
- Parabens (Loba Chemie Pvt. Ltd., Mumbai)
Method of preparation:
GSE mucoadhesive gel preparation:
- Formula 1: 2% GSE mucoadhesive gel based on minimum inhibitory concentration (MIC) and minimum toxic concentration (MTC) and depending on the concentration of adhesive polymers that were added to the formula.
Weighed CB 934 was dissolved in 50 ml of phosphate buffer of pH 6.6 with a vigorous mixing until it dissolved completely. Then, GSE and preservatives were dissolved in about 25 ml of phosphate buffer of pH 6.6. After that, the GSE solution was slowly added into the solution of CB 934 with a continuous stirring that was achieved by magnetic stirring at a speed of 100 rpm until a homogenous mixture was obtained. The gelling agent (Na-CMC) was added slowly under a continuous magnetic stirring. Then, the volume was increased up to 100 ml with the addition of phosphate buffer. Finally, the prepared gel was kept for 24 hours at room temperature (25°C) for a complete polymer dissolution.
- Formula 2: controlled gel without GSE. A controlled mucoadhesive gel was used in the clinical study to be compared with GSE gel. This control gel contained all above mentioned substances except for the GSE.
Microbial limit test:
One gram of the gel was suspended in 2.9 ml of phosphate buffer at pH 7.2. Different sterile media (Bismuth Sulfite Medium, Mannitol salt agar medium, Muller Hinton agar medium, cetrimide agar medium and sabaroud agar medium) were inoculated with the gel, then, incubated for 24 hours. After that, the media were examined to ensure no growth of bacterial genera.
Subjects:
A random sample of 24 patients were screened and examined. Five patients with mean age 43.5 ±7.9 years were found to comply with the study inclusion criteria
Baseline measurements and application of gels A total of 86 Sites of pocket depth (PD) of 5 mm and above were identified. Sites were divided randomly by split mouth technique into two groups: Test group (GSE group) who will receive GSE mucoadhesive gel (N=48) and Control group who will receive the control gel (N=38). The two prepared formulas were placed in identical containers providing that neither the patient, nor the clinician were aware of which was applied on which quadrant of the mouth "i.e. double blinded study".
In the first visit, an informed written consent was obtained from all patients. scaling and root planing (SRP) were performed by the same calibrated examiner using an ultrasonic scaler (miniPiezon, EMS, Switzerland) and Gracey curettes (Hu-Friedy Mfg, USA). Seven days after, the patients were recalled for clinical examination and baseline measurement (T0) were taken for Plaque index (PI), Gingival index (GI), Pocket depth (PD), and bleeding on probing (BOP) by a single calibrated examiner. PD was measured using a manual probe (UNC 15). PI and GI were assessed according to Silness and Loe (1964). BOP was assessed within 30 seconds after probing. In the same visit, the examiner applied the two prepared formulas into two opposite quadrants using a disposable syringe with a 23-gauge needle. Patients were given oral hygiene instructions and were instructed not to drink or eat for a minimum of 3 hours, not to brush the area for 24 hours and not to use mouth wash during the course of treatment.
The patients were recalled again after 3, 6, and 9 days to reapply the two formulas in the examined sites by the same examiner.
Revaluation The first re-evaluation visit (T1) was after 28 days from the baseline measurements (T0). During this visit, the calibrated clinician measured and recorded PI, GI, PD, BOP for all examined sites.
The second re-evaluation visit (T2) was after 6 months from the baseline measurements (T0) and the same measurements were retaken for all sites.
Statistical Package for the Social Sciences (SPSS) v20 package (IBM Corp) was used for statistical analysis. Significance of the change in PI, GI, and PD within each group were determined using paired t-test while the significance of difference in the change between the two groups was determined using the independent t-test. The difference was considered statistically significant at p < 0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GSE mucoadhesive gel | Experimental | Dietary Supplement: 2% GSE mucoadhesive gel2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0 |
| Control mucoadhesive gel | Placebo comparator | Other: GSE free mucoadhesive gelGSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0 |
Who may qualify
- Ages
- 35 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- being medically fit
- non-smokers
- has clinical diagnosis of chronic periodontitis with pockets depth of 5mm or greater along with evident radiographic bone Loss, and acceptance to provide an informed consent
Key exclusion criteria (7 listed)
- pregnant patients
- breastfeeding mothers
- patients who are taking dietary supplements
- patients known to have grape's allergy
- patients with hypertension or bleeding disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2% GSE mucoadhesive gel2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0 | Dietary supplement | GSE mucoadhesive gel |
| GSE free mucoadhesive gelGSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0 | Other | Control mucoadhesive gel |
Primary outcome
Change from baseline Pocket depth (PD) score
Time frame: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
PD will be measured for all sites and compared with PD scores at T0
3 secondary outcomes
Change from baseline Plaque index (PI)score
Time frame: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Change from baseline Gingival index (GI)score
Time frame: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Change from baseline Bleeding on probing (BOP)
Time frame: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2016.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Periodontitis
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
Recruiting
Effect of Cyperus Articulatus on Bacterial Reduction and Postoperative Pain
Chronic Apical Periodontitis
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Recruiting
Postoperative Pain and Success of Single-Visit Root Canal Treatment Using Different Root Canal Sealers in Asymptomatic Teeth
Single-visit, Periapical Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohammad Rayyan, MDS principal investigator
Assistant professor
Tammam S Terkawi, MSc principal investigator
Lecturer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing 2% GSE mucoadhesive gel and GSE free mucoadhesive gel in people with Chronic Periodontitis, run by Riyadh Colleges of Dentistry and Pharmacy at 1 site in Saudi Arabia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline Pocket depth (PD) score (time frame: before application of the gel (baseline T0), 4 weeks after first application (T1), 6 months after first application (T2)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2016.